NASDAQ$PHAT
Phathom Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Phathom Pharmaceuticals reported financial results for the second quarter of 2021 and provided an update on expected clinical and regulatory milestones.
Phathom Pharmaceuticals reported a net loss of $36.6 million for the second quarter of 2021. The company is progressing with its GERD development programs and expects to submit NDAs to the FDA for H. pylori infection treatments in September 2021.
- Topline data from the pivotal Phase 3 PHALCON-EE trial for erosive esophagitis is expected in October 2021.
- Topline data from the Phase 2 PHALCON-NERD on-demand trial for non-erosive reflux disease is now expected in the first quarter of 2022.
- NDAs for dual and triple vonoprazan-based regimens for H. pylori infection treatment are expected to be submitted in September 2021.
- Cash and cash equivalents were $209.7 million as of June 30, 2021, expected to be sufficient into the fourth quarter of 2022.
Headline financials
Revenue & EPS history
Phathom · Revenue · Quarterly
$58.3M
Forward guidance
Phathom anticipates key milestones including topline data from clinical trials and NDA submissions.
Tailwinds
- Topline results from PHALCON-EE trial expected in October 2021.
- Topline results from PHALCON-NERD trial expected in Q1 2022.
- NDA submissions for H. pylori treatments expected in September 2021.
Headwinds
- Potential delays in clinical trials due to the COVID-19 pandemic.
- Dependence on third parties for manufacturing and testing.
- Unexpected adverse side effects or inadequate efficacy of vonoprazan.
- Risk of withdrawal of QIDP and Fast Track designations.
- Ability to maintain undisrupted business operations due to COVID-19.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-2.2%
Avg return
Earnings day
-5.3%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+10.0%
Q1 2023
Best reaction
-22.8%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | +6.9% | -18.6% | |
| Q4 2025 | +9.9% | -10.3% | -14.1% | |
| Q3 2025 | -1.8% | +8.1% | +9.8% | |
| Q1 2025 | -21.7% | -44.1% | -0.9% | |
| Q4 2024 | -3.0% | -21.2% | -19.7% | |
| Q3 2024 | -6.3% | -47.1% | -50.0% | |
| Q2 2024 | +8.7% | +12.6% | +63.9% | |
| Q1 2024 | -5.6% | +2.9% | +5.0% | |
| Q4 2023 | -8.7% | -16.0% | +13.4% | |
| Q3 2023 | -4.0% | -9.2% | +7.8% | |
| Q2 2023 | +3.0% | +2.0% | -15.8% | |
| Q1 2023 | +10.0% | +5.0% | +8.3% | |
| Q4 2022 | -7.1% | -10.0% | -29.9% | |
| Q3 2022 | -9.8% | +4.0% | +5.3% | |
| Q2 2022 | -22.8% | -20.1% | -3.6% | |
| Q1 2022 | -6.3% | -10.5% | -19.7% | |
| Q4 2021 | +2.0% | -4.2% | -24.9% | |
| Q3 2021 | +1.7% | -2.4% | -13.7% | |
| Q2 2021 | +1.5% | -0.1% | +6.6% | |
| Q1 2021 | +6.4% | +0.9% | +5.9% | |
| Q4 2020 | +3.6% | +1.9% | +9.8% | |
| Q3 2020 | -8.6% | -3.0% | +12.6% | |
| Q2 2020 | +5.1% | +12.2% | +5.3% | |
| Q1 2020 | -0.9% | -1.4% | +24.1% | |
| Q4 2019 | -3.2% | -3.2% | +13.5% | |
| Q3 2019 | +6.5% | +9.1% | +9.0% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro